CISD2 and metabolic dysfunction-associated steatotic liver disease: Our mouse studies should provide experimental evidence that will form the basis of a paradigm regarding the functioning of Cisd2 in the development of NAFLD and NASH, and should also help the development of therapeutic strategies aimed at treating NAFLD and NASH.